Latest News

As preclinical CRO expert in AD's and PD's disease research, we are delighted to participate in the 8th Venusberg Meeting on Neuroinflammation.   When: from May, 15th to 17th. Where: on Campus Belval, at University of Luxembourg, in Luxembourg. Poster session: POSTER #2 on May, 15th   🧑‍🔬 Meet our expert during the poster session Dr Ahmad Allouche, Head of in vitro Biology, will be presenting the poster on "Neuroinflammation Models of Neurodegenerative Diseases". Let's meet there to explore our in vitro & in vivo services dedicated to

Le Comité interministériel de l'innovation C2i s'est tenu à Paris le 10 avril 2025, et nous sommes fiers de participer à l'aventure France 2030 pour rapprocher le futur et contribuer à l'excellence française dans la recherche et l’innovation en santé. ETAP-Lab bénéficie depuis plusieurs années du soutien de l'État français pour ses projets d'innovation ambitieux, avec une perspective de croissance significative pour l'entreprise et un rayonnement accru pour la filière biotech française. Nous remercions l’État pour son soutien avec France 2030 pour

ETAP-Lab will participate to the first edition of the Skin Summit, organized by EUROBIOMED. When: April 24 & 25, 2025 Where: Antibes Congress Center, Juan Les Pins, France Who: Jean-François BISSON, PhD, Study Director of our preclinical Dermatology lab, will be present   This prestigious international event will focus on "Next Generation Solutions for Pigmentary Disorders," featuring world-renowned speakers who will share their expertise and insights. These pioneers in their respective fields will present the latest scientific advancements, therapeutic innovations, and best clinical practices. Their

Retrouvez-nous au prochain événement phare des organoïdes et organes sur puce (O&OoC) le 3 avril à l'Institut Curie de Paris organisé par F3OCI ! 📍Nous serons présents en tant que CRO préclinique, fournisseur de services in vitro et in vivo et utilisant des organes-sur-puces dans le cadre du programme BIO-DIAMOND. Nous sommes fiers de sponsoriser ce rendez-vous des chercheurs académiques, biotechnologies et groupes pharmaceutiques de la filière ! Dr Valentin Tallandier, in vitro preclinical Project leader, présentera un pitch à 16:45 – 17:00

📌 Let's meet in San Diego (USA) - April 5-9, 2025 - booth #2043 Our team will be delighted to welcome you at the AAN 2025 Annual Meeting, "The best and largest gathering for neurologists and neuroscience professionals"! This year, we'll be exhibiting at booth #2043 where you'll discover our relevant & translatable in vitro and in vivo solutions for neurology & neurovascular disorders. 🧠 You'll learn more about Brain-on-Chip for PoC on your targets, models of proteinopathies & other neuronal injuries, our

📌 See you in Vienna (Austria) - from 1st to 5th April 2025! We are participating in the 40th AD/PD 2025 as a preclinical CRO expert in AD's and PD's disease research . 📅 Stop by our booth #25 Alzheimer’s & Parkinson’s Diseases Conference is a leading event in the field of neurodegenerative diseases and this year we are exhibiting on booth #25 to present our in vitro & in vivo services dedicated to AD's & PD's translational neuroscience, especially focused on proteinopathies

Brain-on-chips (BoC) are innovative tools that simulate complex brain environments, enhancing our understanding of neurodegenerative diseases (NDDs). While a range of BoC platforms have been developed to model diverse NDD pathophysiologies, the various channel architectures of these microfluidic devices present challenges in image acquisition and analysis. High-content imaging protocols must be adaptable to these differing designs.   This Technical Note, developed by Revvity in collaboration with ETAP-Lab, demonstrates an automated image acquisition protocol for BoC microfluidic devices. The protocol utilizes the Operetta

Cardiovascular diseases (CVDs) are the leading cause of global mortality. That's why we are proud to share a groundbreaking study titled "Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers". Liu, Sophia et al. iScience, Volume 28, Issue 2, 111814   This study highlights the potential of Urolithin A (UA), a post-biotic and mitophagy activator, to improve heart health by addressing mitochondrial dysfunctions. Preclinical model results show reduced cardiac dysfunction, while human trials indicate significant reductions